The aim of this study was to specifically investigate impact of experimental and clinical diabetes on CB-ECFC angiogenic function in relation to NOX4 signalling towards identification of key mediators as candidates for selective targeting to enhance therapeutic efficacy in this setting. Here, NOX4 is linked to diabetes mellitus.